Key Highlights
● Weiss Asset Management reported zero shares of Theravance Biopharma in a 13D/A filed September 25, 2026, the fourth amendment to its 2023 filing.
● Theravance's shares were cancelled on September 23, 2026 when its Merger with Zymeworks Inc. closed.
● The four reporting persons did not sell any shares in the prior 60 days; the position was eliminated by the merger's share cancellation.
● The filing does not disclose the merger's exchange ratio or consideration, which would appear in separate merger-related filings.
Weiss Asset Management and its affiliates reported holding zero shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in a Schedule 13D/A filed September 25, 2026, after the company's stock was cancelled when its merger with Zymeworks Inc. closed on September 23, 2026. The amendment, the fourth to Weiss's original 2023 filing, formally closes out a beneficial-ownership position that once made the fund one of Theravance's disclosed holders. It was filed with the SEC the same week the merger closed, reflecting the routine practice of updating ownership disclosures promptly after a triggering corporate event.
What the Filing Says Happened
The amendment states directly that "the Issuer's Shares were cancelled on September 23, 2026 in connection with the completion of the merger with Zymeworks Inc." As a result, all four reporting persons named in the filing, Weiss Asset Management LP, BIP GP LLC, WAM GP LLC and Andrew M. Weiss individually, now report 0% ownership of Theravance, calculated against the 51,918,754 shares that had been outstanding as of July 31, 2026.
The filing also states that "the Reporting Persons did not effect any transactions in the Issuer's Shares during the past 60 days," meaning Weiss did not sell out of the position ahead of the deal; the shares simply ceased to exist as a class when the merger closed. The filing lists the same four reporting persons that appeared in Weiss's earlier amendments, preserving continuity in how the fund's Theravance-related holdings had been tracked since 2023 even as the position is now reduced to zero.
A Routine Closing-Out Filing
Schedule 13D amendments of this kind are procedural: once a reporting person's stake in a company drops to zero, whether through a sale, a merger, or a cancellation of shares, SEC rules generally call for a final amendment to reflect the exit and terminate the reporting obligation. Because Theravance's shares were cancelled as a mechanical step in closing the merger, rather than through Weiss choosing to sell, this filing functions more as a record-keeping formality than a disclosure of new Investment activity.
The filing gives no additional detail about the terms of the Zymeworks merger itself, such as the exchange ratio or consideration paid to Theravance shareholders, since a Schedule 13D/A is not the vehicle for disclosing merger consideration; that information would have appeared in Theravance's own merger-related filings, such as a proxy statement or Form 8-K describing the transaction's closing. A Schedule 13D/A exists solely to update a specific reporting person's ownership stake and stated intentions, not to summarize the underlying corporate transaction that caused the change.
Background on the Companies
Theravance Biopharma is a Cayman Islands-incorporated biopharmaceutical company, and Zymeworks is a clinical-stage biotechnology company; the combination that closed September 23 brought the two together, with Theravance's stock cancelled as part of that transaction structure. Weiss Asset Management is a Boston-based investment adviser that had held a stake in Theravance since at least 2023, based on the original 13D's filing date referenced in this amendment. Weiss's earlier amendments to the same 13D would have tracked the fund's Theravance position through years of corporate developments, culminating now in the position's complete elimination as a result of the merger's closing mechanics.
Where Merger Terms Can Be Found
This 13D/A appears to be a final amendment for Weiss's Theravance position, since the reporting persons now hold zero shares; no further amendments would ordinarily be expected absent a new stake. Investors seeking the specific terms of the Zymeworks merger, including exchange ratio, closing conditions, and surviving entity structure, should look to Theravance's and Zymeworks' own merger-related SEC filings, which are separate from this ownership amendment. No further transactions or purpose-of-transaction changes are disclosed here, and this filing does not itself disclose any consideration Theravance shareholders may have received in the merger.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...